Search

Your search keyword '"Hauser, Stephen"' showing total 154 results
Start Over Author "Hauser, Stephen" Journal neurology
154 results on '"Hauser, Stephen"'

1. Safety of Ocrelizumab in Patients With Relapsing and Primary Progressive Multiple Sclerosis

Author

Hauser, Stephen L, Kappos, Ludwig, Montalban, Xavier, Craveiro, Licinio, Chognot, Cathy, Hughes, Richard, Koendgen, Harold, Pasquarelli, Noemi, Pradhan, Ashish, Prajapati, Kalpesh, and Wolinsky, Jerry S

Subjects
Biomedical and Clinical Sciences, Clinical Sciences, Clinical Research, Brain Disorders, Multiple Sclerosis, Neurodegenerative, Clinical Trials and Supportive Activities, Patient Safety, Neurosciences, Adolescent, Adult, Aged, Antibodies, Monoclonal, Humanized, Clinical Trials as Topic, Drug-Related Side Effects and Adverse Reactions, Female, Humans, Male, Middle Aged, Multiple Sclerosis, Chronic Progressive, Multiple Sclerosis, Relapsing-Remitting, Young Adult, Cognitive Sciences, Neurology & Neurosurgery, Clinical sciences
Abstract

Background and objectivesTo report safety of ocrelizumab (OCR) up to 7 years in patients with relapsing multiple sclerosis (RMS) and primary progressive multiple sclerosis (PPMS) enrolled in clinical trials or treated in real-world postmarketing settings.MethodsSafety analyses are based on integrated clinical and laboratory data for all patients who received OCR in 11 clinical trials, including the controlled treatment and open-label extension (OLE) periods of the phase 2 and 3 trials, plus the phase 3b trials VELOCE, CHORDS, CASTING, OBOE, ENSEMBLE, CONSONANCE, and LIBERTO. For selected adverse events (AEs), additional postmarketing data were used. Incidence rates of serious infections (SIs) and malignancies were contextualized using multiple epidemiologic sources.ResultsAt data cutoff (January 2020), 5,680 patients with multiple sclerosis (MS) received OCR (18,218 patient-years [PY] of exposure) in clinical trials. Rates per 100 PY (95% confidence interval) of AEs (248; 246-251), serious AEs (7.3; 7.0-7.7), infusion-related reactions (25.9; 25.1-26.6), and infections (76.2; 74.9-77.4) were similar to those within the controlled treatment period of the phase 3 trials. Rates of the most common serious AEs, including SIs (2.01; 1.81-2.23) and malignancies (0.46; 0.37-0.57), were consistent with the ranges reported in epidemiologic data.DiscussionContinuous administration of OCR for up to 7 years in clinical trials, as well as its broader use for more than 3 years in the real-world setting, are associated with a favorable and manageable safety profile, without emerging safety concerns, in a heterogeneous MS population.Classification of evidenceThis analysis provides Class III evidence that long-term, continuous treatment with OCR has a consistent and favorable safety profile in patients with RMS and PPMS. This study is rated Class III because of the use of OLE data and historical controls.

Published
2021

2. Five-years of ocrelizumab in relapsing multiple sclerosis: OPERA studies open-label extension

Author

Hauser, Stephen L, Kappos, Ludwig, Arnold, Douglas L, Bar-Or, Amit, Brochet, Bruno, Naismith, Robert T, Traboulsee, Anthony, Wolinsky, Jerry S, Belachew, Shibeshih, Koendgen, Harold, Levesque, Victoria, Manfrini, Marianna, Model, Fabian, Hubeaux, Stanislas, Mehta, Lahar, and Montalban, Xavier

Subjects
Biomedical and Clinical Sciences, Clinical Sciences, Clinical Research, Neurosciences, Brain Disorders, Clinical Trials and Supportive Activities, 6.1 Pharmaceuticals, Evaluation of treatments and therapeutic interventions, Neurological, Adult, Antibodies, Monoclonal, Humanized, Brain, Female, Follow-Up Studies, Humans, Immunologic Factors, Magnetic Resonance Imaging, Male, Multiple Sclerosis, Relapsing-Remitting, Neuroimaging, Randomized Controlled Trials as Topic, Recurrence, Time Factors, Treatment Outcome, Cognitive Sciences, Neurology & Neurosurgery, Clinical sciences
Abstract

ObjectiveTo assess over 3 years of follow-up the effects of maintaining or switching to ocrelizumab (OCR) therapy on clinical and MRI outcomes and safety measures in the open-label extension (OLE) phase of the pooled OPERA: I/II studies in relapsing multiple sclerosis.MethodsAfter 2 years of double-blind, controlled treatment, patients continued OCR (600 mg infusions every 24 weeks) or switched from interferon (IFN)-β-1a (44 μg 3 times weekly) to OCR when entering the OLE phase (3 years). Adjusted annualized relapse rate, time to onset of 24-week confirmed disability progression (CDP)/improvement (CDP), brain MRI activity (gadolinium-enhanced and new/enlarging T2 lesions), and percentage brain volume change were analyzed.ResultsOf patients entering the OLE phase, 88.6% completed year 5. The cumulative proportion with 24-week CDP was lower in patients who initiated OCR earlier vs patients initially receiving IFN-β-1a (16.1% vs 21.3% at year 5; p = 0.014). Patients continuing OCR maintained and those switching from IFN-β-1a to OCR attained near complete and sustained suppression of new brain MRI lesion activity from years 3-5. Over the OLE phase, patients continuing OCR exhibited less whole brain volume loss from double-blind study baseline vs those switching from IFN-β-1a (-1.87% vs -2.15% at year 5; p < 0.01). Adverse events were consistent with past reports and no new safety signals emerged with prolonged treatment.ConclusionCompared with patients switching from IFN-β-1a, earlier and continuous OCR treatment up to 5 years provided sustained benefit on clinical and MRI measures of disease progression.Classification of evidenceThis study provides Class III evidence that earlier and continuous treatment with OCR provided sustained benefit on clinical and MRI outcomes of disease activity and progression compared with patients switching from IFN-β-1a. The study is rated Class III because of the initial treatment randomization disclosure that occurred after inclusion in OLE.Clinical trial identifiersNCT01247324/NCT01412333.

Published
2020

3. Onset of clinical and MRI efficacy of ocrelizumab in relapsing multiple sclerosis

Author

Barkhof, Frederik, Kappos, Ludwig, Wolinsky, Jerry S, Li, David KB, Bar-Or, Amit, Hartung, Hans-Peter, Belachew, Shibeshih, Han, Jian, Julian, Laura, Sauter, Annette, Napieralski, Julie, Koendgen, Harold, and Hauser, Stephen L

Subjects
Clinical Trials and Supportive Activities, Neurosciences, Rare Diseases, Multiple Sclerosis, Clinical Research, Brain Disorders, Neurodegenerative, 6.1 Pharmaceuticals, Evaluation of treatments and therapeutic interventions, Cancer, Adjuvants, Immunologic, Adult, Antibodies, Monoclonal, Humanized, Brain, Female, Humans, Immunologic Factors, Interferon beta-1a, Magnetic Resonance Imaging, Male, Middle Aged, Multiple Sclerosis, Relapsing-Remitting, Recurrence, Time Factors, Treatment Outcome, Clinical Sciences, Cognitive Sciences, Neurology & Neurosurgery
Abstract

OBJECTIVE:To assess the onset of ocrelizumab efficacy on brain MRI measures of disease activity in the phase II study in relapsing-remitting multiple sclerosis (RRMS), and relapse rate in the pooled phase III studies in relapsing multiple sclerosis (RMS). METHODS:Brain MRI activity was determined in the phase II trial at monthly intervals in patients with RRMS receiving placebo, ocrelizumab (600 mg), or intramuscular interferon (IFN) β-1a (30 μg). Annualized relapse rate (ARR; over various epochs) and time to first relapse were analyzed in the pooled population of the phase III OPERA (A Study of Ocrelizumab in Comparison With Interferon Beta-1a [Rebif] in Participants With Relapsing Multiple Sclerosis) I and OPERA II trials in patients with RMS receiving ocrelizumab (600 mg) or subcutaneous IFN-β-1a (44 μg). RESULTS:In patients with RRMS, ocrelizumab reduced the number of new T1 gadolinium-enhancing lesions by week 4 vs placebo (p = 0.042) and by week 8 vs intramuscular IFN-β-1a (p < 0.001). Ocrelizumab also reduced the number of new or enlarging T2 lesions appearing between weeks 4 and 8 vs both placebo and IFN-β-1a (both p < 0.001). In patients with RMS, ocrelizumab significantly reduced ARR (p = 0.005) and the probability of time to first protocol-defined relapse (p = 0.014) vs subcutaneous IFN-β-1a within the first 8 weeks. CONCLUSION:Epoch analysis of MRI-measured lesion activity in the phase II study and relapse rate in the phase III studies consistently revealed a rapid suppression of acute MRI and clinical disease activity following treatment initiation with ocrelizumab in patients with RRMS and RMS, respectively. CLASSIFICATION OF EVIDENCE:This study provides Class II evidence that for patients with RRMS and RMS, ocrelizumab suppressed MRI activity within 4 weeks and clinical disease activity within 8 weeks.

Published
2019

4. Prognostic Value of On-treatment Serum Neurofilament Light Chain for New or Enlarging T2 Lesions in People with Relapsing Multiple Sclerosis: Pooled Analysis of the ASCLEPIOS I/II Trials (S42.003)

Author

Leist, Thomas, primary, Hauser, Stephen, additional, Derfuss, Tobias, additional, Wiendl, Heinz, additional, Arnold, Douglas, additional, Montalban, Xavier, additional, Bhatt, Alit, additional, Wei, Wenjia, additional, Boer, Ibolya, additional, Alvarez, Enrique, additional, and Ziemssen, Tjalf, additional

Published
2024
Full Text
View/download PDF

5. Synaptic Injury in the IPL of the Retina Is a Predictor of Progression in Multiple Sclerosis (P6-6.003)

Author

Cordano, Christian, primary, Werneburg, Sebastian, additional, Abdelhak, Ahmed, additional, Bennett, Daniel, additional, Beaudry-richard, Alexandra, additional, Duncan, Greg, additional, Oertel, Frederike, additional, Boscardin, John, additional, Yiu, Hao, additional, Jabassini, Nora, additional, Merritt, Lauren, additional, Nocera, Sonia, additional, Sin, Jung, additional, Montes, Shivany Condor, additional, Ananth, Kirtana, additional, Bischof, Antje, additional, Nourbakhsh, Bardia, additional, Hauser, Stephen, additional, Cree, Bruce, additional, Emery, Ben, additional, Chan, Jonah, additional, Schafer, Dorothy, additional, and Green, Ari, additional

Published
2024
Full Text
View/download PDF

6. Longer-term Safety and Efficacy of Ofatumumab in People with Relapsing Multiple Sclerosis for Up to 6 Years (P9-6.010)

Author

Wiendl, Heinz, primary, Hauser, Stephen, additional, Nicholas, Jacqueline, additional, De Seze, Jerome, additional, Meuth, Sven, additional, Giacomini, Paul, additional, Robertson, Derrick, additional, Wray, Sibyl, additional, Bhatt, Alit, additional, Hu, Xixi, additional, Fu, Haoyi, additional, Jehl, Valentine, additional, Sullivan, Roseanne, additional, Boer, Ibolya, additional, Cohen, Jeffrey, additional, and Kappos, Ludwig, additional

Published
2024
Full Text
View/download PDF

7. B-Cell Depletion and Efficacy Outcomes of Ofatumumab Are Consistent Across Different Body Mass Index Categories: Insights from ASCLEPIOS I and II Trials (P9-6.002)

Author

Cross, Anne, primary, Hauser, Stephen, additional, Wiendl, Heinz, additional, Bar-Or, Amit, additional, Coyle, Patricia, additional, Montalban, Xavier, additional, De Seze, Jerome, additional, Fu, Haoyi, additional, Bhatt, Alit, additional, Boer, Ibolya, additional, and Kappos, Ludwig, additional

Published
2024
Full Text
View/download PDF

8. B Cell-mediated Neurotoxicity in Multiple Sclerosis (P7-6.003)

Author

Saha, Chaitrali, primary, Zhang, Amy, additional, Leng, Kun, additional, Gerungan, Chloe, additional, Abdelhak, Ahmed, additional, Gomez, Refujia, additional, Harms, Meagan, additional, Tubati, Asritha, additional, Cooper, Tiffany, additional, Louine, Martineau, additional, Sabatino, Joseph, additional, Kampmann, Martin, additional, Green, Ari, additional, Oksenberg, Jorge, additional, Cree, Bruce, additional, Wilson, Michael, additional, and Hauser, Stephen, additional

Published
2024
Full Text
View/download PDF

9. Body mass index, but not vitamin D status, is associated with brain volume change in MS.

Author

Mowry, Ellen M, Azevedo, Christina J, McCulloch, Charles E, Okuda, Darin T, Lincoln, Robin R, Waubant, Emmanuelle, Hauser, Stephen L, and Pelletier, Daniel

Subjects
Clinical Trials and Supportive Activities, Nutrition, Neurosciences, Multiple Sclerosis, Clinical Research, Aging, Prevention, Brain Disorders, Neurodegenerative, Neurological, Adult, Body Mass Index, Brain, Female, Gray Matter, Humans, Magnetic Resonance Imaging, Male, Middle Aged, Vitamin D, White Matter, Clinical Sciences, Cognitive Sciences, Neurology & Neurosurgery
Abstract

ObjectiveTo determine whether body mass index (BMI) or vitamin D status is associated with MRI measures of neurodegeneration in a cohort of individuals with relapsing-remitting multiple sclerosis (RRMS) or clinically isolated syndrome (CIS).MethodsExpression, Proteomics, Imaging, Clinical (EPIC) is a longitudinal multiple sclerosis (MS) cohort study at the University of California, San Francisco. Participants had clinical evaluations, brain MRI, and blood draws annually. We evaluated patients with CIS or RRMS at baseline. In multivariate repeated-measures analyses adjusted for age, sex, ethnicity, smoking status, and use of MS treatments, annual 25-hydroxyvitamin D levels and BMI were evaluated for their association with subsequent brain volumes (normalized gray matter [nGMV], brain parenchymal [nBPV], and white matter volumes, as determined by Structural Image Evaluation using Normalization of Atrophy-X).ResultsAmong 469 participants, each 1-kg/m2 higher BMI was independently associated with reduced nGMV in multivariate models (-1.1 mL, 95% confidence interval [CI] -1.8 to -0.5, p = 0.001). BMI was likewise independently associated with nBPV (nBPV per 1-kg/m2 greater BMI: -1.1 mL, 95% CI -2.1 to -0.05, p = 0.039). Vitamin D levels did not appear to be meaningfully associated with brain volumes.ConclusionsHigher BMI appears to be associated with greater reductions in nGMV and nBPV, which is relevant because, in particular, nGMV loss portends greater longer-term disability. Because obesity is modifiable, further studies should explore these relationships in detail, and evaluating the effect of reducing BMI on imaging and clinical outcomes in MS may be warranted.

Published
2018

10. Ovarian aging is associated with gray matter volume and disability in women with MS.

Author

Graves, Jennifer S, Henry, Roland G, Cree, Bruce AC, Lambert-Messerlian, Geralyn, Greenblatt, Ruth M, Waubant, Emmanuelle, Cedars, Marcelle I, Zhu, Alyssa, University of California, San Francisco MS-EPIC Team,, Bacchetti, Peter, Hauser, Stephen L, and Oksenberg, Jorge R

Subjects
University of California, San Francisco MS-EPIC Team, Ovary, Humans, Multiple Sclerosis, Magnetic Resonance Imaging, Disability Evaluation, Case-Control Studies, Longitudinal Studies, Follow-Up Studies, Cross-Sectional Studies, Aging, Adult, Aged, Middle Aged, Female, Anti-Mullerian Hormone, Young Adult, Gray Matter, Biomarkers, Clinical Research, Clinical Sciences, Neurosciences, Cognitive Sciences, Neurology & Neurosurgery
Abstract

OBJECTIVE:To determine if ovarian aging as measured by levels of anti-Müllerian hormone (AMH) is associated with pattern of multiple sclerosis (MS) progression in women. METHODS:Women with MS and healthy controls were included from a longitudinal research cohort with up to 10 years follow-up. Plasma AMH levels were measured by ELISA for baseline and years 3, 5, and 8-10. Mixed effects logistic and linear regression models were employed, with adjustments for age, disease duration, and other covariables as appropriate. RESULTS:AMH levels were similar (0.98-fold difference, 95% confidence interval [CI] 0.69-1.37, p = 0.87) in women with MS (n = 412, mean age 42.6 years) and healthy controls (n = 180, mean age 44 years). In a multivariable model of women with MS, including adjustments for age, body mass index, and disease duration, 10-fold lower AMH level was associated with 0.43-higher Expanded Disability Status Scale (EDSS) score (95% CI 0.15-0.70, p = 0.003), 0.25-unit worse MS Functional Composite z score (95% CI -0.40 to -0.10, p = 0.0015), and 7.44 mm3 lower cortical gray matter volume (95% CI -14.6 to -0.30; p = 0.041) at baseline. In a multivariable random-intercept-random-slope model using all observations over time, 10-fold decrease in AMH was associated with a 0.27 increase in EDSS (95% CI 0.11-0.43, p = 0.006) and 5.48 mm3 (95% CI 11.3-0.33, p = 0.065) and 4.55 mm3 (95% CI 9.33-0.23, p = 0.062) decreases in total gray and cortical gray matter, respectively. CONCLUSION:As a marker of ovarian aging, lower AMH levels were associated with greater disability and gray matter loss in women with MS independent of chronological age and disease duration.

Published
2018

11. Infliximab for the treatment of CNS sarcoidosis

Author

Gelfand, Jeffrey M, Bradshaw, Michael J, Stern, Barney J, Clifford, David B, Wang, Yunxia, Cho, Tracey A, Koth, Laura L, Hauser, Stephen L, Dierkhising, Jason, Vu, NgocHanh, Sriram, Subramaniam, Moses, Harold, Bagnato, Francesca, Kaufmann, Jeffrey A, Ammah, Deidre J, Yohannes, Tsion H, Hamblin, Mark J, Venna, Nagagopal, Green, Ari J, and Pawate, Siddharama

Subjects
Neurosciences, Clinical Research, Biomedical Imaging, Brain Disorders, Autoimmune Disease, Adult, Aged, Central Nervous System Diseases, Female, Humans, Immunosuppressive Agents, Infliximab, Male, Middle Aged, Outcome Assessment, Health Care, Sarcoidosis, Tumor Necrosis Factor-alpha, Young Adult, Clinical Sciences, Cognitive Sciences, Neurology & Neurosurgery
Abstract

ObjectiveTo describe clinical and imaging responses in neurosarcoidosis to infliximab, a monoclonal antibody against tumor necrosis factor-α.MethodsInvestigators at 6 US centers retrospectively identified patients with CNS sarcoidosis treated with infliximab, including only patients with definite or probable neurosarcoidosis following rigorous exclusion of other causes.ResultsOf 66 patients with CNS sarcoidosis (27 definite, 39 probable) treated with infliximab for a median of 1.5 years, the mean age was 47.5 years at infliximab initiation (SD 11.7, range 24-71 years); 56.1% were female; 62.1% were white, 37.0% African American, and 3% Hispanic. Sarcoidosis was isolated to the CNS in 19.7%. Using infliximab doses ranging from 3 to 7 mg/kg every 4-8 weeks, MRI evidence of a favorable treatment response was observed in 82.1% of patients with imaging follow-up (n = 56), with complete remission of active disease in 51.8% and partial MRI improvement in 30.1%; MRI worsened in 1 patient (1.8%). There was clinical improvement in 77.3% of patients, with complete neurologic recovery in 28.8%, partial improvement in 48.5%, clinical stability in 18.2%, worsening in 3%, and 1 lost to follow-up. In 16 patients in remission when infliximab was discontinued, the disease recurred in 9 (56%), typically in the same neuroanatomic location.ConclusionsMost patients with CNS sarcoidosis treated with infliximab exhibit favorable imaging and clinical treatment responses, including some previously refractory to other immunosuppressive treatments.Classification of evidenceThis study provides Class IV evidence that for patients with CNS sarcoidosis infliximab is associated with favorable imaging and clinical responses.

Published
2017

12. Mitochondrial DNA sequence variation in multiple sclerosis

Author

Tranah, Gregory J, Santaniello, Adam, Caillier, Stacy J, D'Alfonso, Sandra, Martinelli Boneschi, Filippo, Hauser, Stephen L, and Oksenberg, Jorge R

Subjects
Biomedical and Clinical Sciences, Neurosciences, Clinical Sciences, Brain Disorders, Multiple Sclerosis, Human Genome, Clinical Research, Genetics, Neurodegenerative, Aetiology, 2.1 Biological and endogenous factors, Neurological, Case-Control Studies, DNA, Mitochondrial, Genetic Predisposition to Disease, Genetic Variation, Genome-Wide Association Study, Haplotypes, Humans, Polymorphism, Single Nucleotide, White People, Cognitive Sciences, Neurology & Neurosurgery, Clinical sciences
Abstract

ObjectiveTo assess the influence of common mitochondrial DNA (mtDNA) sequence variation on multiple sclerosis (MS) risk in cases and controls part of an international consortium.MethodsWe analyzed 115 high-quality mtDNA variants and common haplogroups from a previously published genome-wide association study among 7,391 cases from the International Multiple Sclerosis Genetics Consortium and 14,568 controls from the Wellcome Trust Case Control Consortium 2 project from 7 countries. Significant single nucleotide polymorphism and haplogroup associations were replicated in 3,720 cases and 879 controls from the University of California, San Francisco.ResultsAn elevated risk of MS was detected among haplogroup JT carriers from 7 pooled clinic sites (odds ratio [OR] = 1.15, 95% confidence interval [CI] = 1.07-1.24, p = 0.0002) included in the discovery study. The increased risk of MS was observed for both haplogroup T (OR = 1.17, 95% CI = 1.06-1.29, p = 0.002) and haplogroup J carriers (OR = 1.11, 95% CI = 1.01-1.22, p = 0.03). These haplogroup associations with MS were not replicated in the independent sample set. An elevated risk of primary progressive (PP) MS was detected for haplogroup J participants from 3 European discovery populations (OR = 1.49, 95% CI = 1.10-2.01, p = 0.009). This elevated risk was borderline significant in the US replication population (OR = 1.43, 95% CI = 0.99-2.08, p = 0.058) and remained significant in pooled analysis of discovery and replication studies (OR = 1.43, 95% CI = 1.14-1.81, p = 0.002). No common individual mtDNA variants were associated with MS risk.ConclusionsIdentification and validation of mitochondrial genetic variants associated with MS and PPMS may lead to new targets for treatment and diagnostic tests for identifying potential responders to interventions that target mitochondria.

Published
2015

13. Genetic risk variants in African Americans with multiple sclerosis.

Author

Isobe, Noriko, Harbo, Hanne, Caillier, Stacy, Santaniello, Adam, Khankhanian, Pouya, Maiers, Martin, Spellman, Stephen, Cereb, Nezih, Yang, SooYoung, Pando, Marcelo, Piccio, Laura, Cross, Anne, De Jager, Philip, Hauser, Stephen, Oksenberg, Jorge, Cree, Bruce, and Gourraud, Pierre-Antoine

Subjects
Adult, Black or African American, Age of Onset, Alleles, Case-Control Studies, Female, Genetic Association Studies, Genetic Predisposition to Disease, Genotype, HLA-A Antigens, HLA-DQ beta-Chains, HLA-DRB1 Chains, Humans, Male, Middle Aged, Multiple Sclerosis, Polymorphism, Single Nucleotide
Abstract

OBJECTIVES: To assess the association of established multiple sclerosis (MS) risk variants in 3,254 African Americans (1,162 cases and 2,092 controls). METHODS: Human leukocyte antigen (HLA)-DRB1, HLA-DQB1, and HLA-A alleles were typed by molecular techniques. Single nucleotide polymorphism (SNP) genotyping was conducted for 76 MS-associated SNPs and 52 ancestry informative marker SNPs selected throughout the genome. Self-declared ancestry was refined by principal component analysis of the ancestry informative marker SNPs. An ancestry-adjusted multivariate model was applied to assess genetic associations. RESULTS: The following major histocompatibility complex risk alleles were replicated: HLA-DRB1*15:01 (odds ratio [OR] = 2.02 [95% confidence interval: 1.54-2.63], p = 2.50e-07), HLA-DRB1*03:01 (OR = 1.58 [1.29-1.94], p = 1.11e-05), as well as HLA-DRB1*04:05 (OR = 2.35 [1.26-4.37], p = 0.007) and the African-specific risk allele of HLA-DRB1*15:03 (OR = 1.26 [1.05-1.51], p = 0.012). The protective association of HLA-A*02:01 was confirmed (OR = 0.72 [0.55-0.93], p = 0.013). None of the HLA-DQB1 alleles were associated with MS. Using a significance threshold of p < 0.01, outside the major histocompatibility complex region, 8 MS SNPs were also found to be associated with MS in African Americans. CONCLUSION: MS genetic risk in African Americans only partially overlaps with that of Europeans and could explain the difference of MS prevalence between populations.

Published
2013

14. Accelerated Worsening in Serum Neurofilament Light Chain Levels and Multiple Sclerosis Functional Composite in Women with MS after Menopause (S9.009)

Author

Silverman, Hannah, primary, Bostrom, Alan, additional, Lazar, Ann, additional, Gomez, Refujia, additional, Santaniello, Adam, additional, Renschen, Adam, additional, Harms, Meagan, additional, Cooper, Tiffany, additional, Lincoln, Robin, additional, Poole, Shane, additional, Henry, Roland, additional, Oksenberg, Jorge, additional, Hauser, Stephen, additional, Cree, Bruce A. C., additional, and Bove, Riley, additional

Published
2023
Full Text
View/download PDF

16. Differences in Age-related Retinal and Cortical Atrophy Rates in Multiple Sclerosis

Author

Cordano, Christian, primary, Nourbakhsh, Bardia, additional, Yiu, Hao H., additional, Papinutto, Nico, additional, Caverzasi, Eduardo, additional, Abdelhak, Ahmed, additional, Oertel, Frederike C., additional, Beaudry-Richard, Alexandra, additional, Santaniello, Adam, additional, Sacco, Simone, additional, Bennett, Daniel J., additional, Gomez, Apraham, additional, Sigurdson, Christina J., additional, Hauser, Stephen L., additional, Magliozzi, Roberta, additional, Cree, Bruce A.C., additional, Henry, Roland G., additional, and Green, Ari J., additional

Published
2022
Full Text
View/download PDF

17. Long-Term Suppression of MRI Disease Activity and Reduction of Global/Regional Volume Loss: Results from OPERA I/II and ORATORIO Open-Label Extension (P6-4.002)

Author

Arnold, Douglas, primary, Traboulsee, Anthony, additional, Wolinsky, Jerry, additional, Hauser, Stephen, additional, Kappos, Ludwig, additional, Montalban, Xavier, additional, Barkhof, Frederik, additional, Bonati, Ulrike, additional, Wei, Wei, additional, and Gaetano, Laura, additional

Published
2022
Full Text
View/download PDF

20. Long-term Safety of Ofatumumab in Patients With Relapsing Multiple Sclerosis (S14.004)

Author

Hauser, Stephen L., primary, Cross, Anne H., additional, Winthrop, Kevin, additional, Wiendl, Heinz, additional, Nicholas, Jacqueline, additional, Meuth, Sven G., additional, Giacomini, Paul S., additional, Saccà, Francesco, additional, Zielman, Ronald, additional, Gupta, Ayan Das, additional, Hu, Xixi, additional, Pingili, Ratnakar, additional, Sullivan, Roseanne, additional, DeLasHeras, Virginia, additional, Su, Wendy, additional, and Kappos, Ludwig, additional

Published
2022
Full Text
View/download PDF

23. Effect of Ofatumumab on Serum Immunoglobulin Levels and Infection Risk in Relapsing Multiple Sclerosis (RMS) Patients from the Phase 3 ASCLEPIOS I and II Trials (1300)

Author

Bar-Or, Amit, primary, De Seze, Jerome, additional, Correale, Jorge, additional, Cross, Anne, additional, Kappos, Ludwig, additional, Selmaj, Krzysztof, additional, Wiendl, Heinz, additional, Kerloeguen, Cecile, additional, Pingili, Ratnakar, additional, Sullivan, Roseanne, additional, Gupta, Ayan Das, additional, Jehl, Valentine, additional, Haering, Dieter, additional, Merschhemke, Martin, additional, and Hauser, Stephen, additional

Published
2021
Full Text
View/download PDF

25. Quantitative MRI Reveals Mild Cervical Cord Damage in Longstanding Relapsing Multiple Sclerosis (2189)

Author

Bischof, Antje, primary, Cheng, Shuiting, additional, Cree, Bruce, additional, Rajesh, Anand, additional, Kirkish, Gina, additional, Gundel, Tristan, additional, Stern, William, additional, Juwono, Jeremy, additional, Asteggiano, Carlo, additional, Santaniello, Adam, additional, Caverzasi, Eduardo, additional, Bove, Riley, additional, Gelfand, Jeffrey, additional, Green, Ari, additional, Guo, Chu-Yueh, additional, Sabatino, Joseph, additional, Waubant, Emmanuelle, additional, Wilson, Michael, additional, Zamvil, Scott, additional, Hauser, Stephen, additional, Papinutto, Nico, additional, and Henry, Roland, additional

Published
2021
Full Text
View/download PDF

26. Prognostic Value of Serum NfL for Subclinical Disease Activity and Worsening in Patients with RMS: Results from the Phase 3 ASCLEPIOS I and II Trials (4069)

Author

Ziemssen, Tjalf, primary, Arnold, Douglas L., additional, Alvarez, Enrique, additional, Cross, Anne H., additional, Willi, Roman, additional, Li, Bingbing, additional, Kukkaro, Petra, additional, Kropshofer, Harald, additional, Ramanathan, Krishnan, additional, Merschhemke, Martin, additional, Su, Wendy, additional, Haering, Dieter A., additional, Hauser, Stephen L., additional, Kappos, Ludwig, additional, and Kuhle, Jens, additional

Published
2021
Full Text
View/download PDF

27. Long-term Reduction of Confirmed Disability Progression and Time to Walking Aid After 6 Years of Ocrelizumab Treatment in Patients with Relapsing Multiple Sclerosis (1847)

Author

Giovannoni, Gavin, primary, Kappos, Ludwig, additional, de Seze, Jerome, additional, Hauser, Stephen, additional, Overell, James, additional, Koendgen, Harold, additional, Prajapati, Kalpesh, additional, Manfrini, Marianna, additional, Wang, Qing, additional, and Wolinsky, Jerry, additional

Published
2020
Full Text
View/download PDF

28. Factors associated with baseline serum neurofilament light concentrations in relapsing and primary progressive multiple sclerosis patients in the ocrelizumab OPERA 1 and ORATORIO Trials (2420)

Author

Bar-Or, Amit, primary, Thanei, Gian-Andrea, additional, Harp, Christopher, additional, Cross, Anne, additional, Fiore, Damian, additional, Hauser, Stephen, additional, Jia, Xiaoming, additional, Kappos, Ludwig, additional, Koendgen, Harold, additional, Kuhle, Jens, additional, Leppert, David, additional, Manfrini, Marianna, additional, Model, Fabian, additional, Sauter, Annette, additional, and Herman, Ann, additional

Published
2020
Full Text
View/download PDF

29. B-cell Depletion and Efficacy Outcomes with Ofatumumab: Subgroup Analysis From the Pooled Phase 3 ASCLEPIOS I and II Trials (2356)

Author

Hauser, Stephen, primary, Bar-Or, Amit, additional, Cohen, Jeffrey A., additional, Comi, Giancarlo, additional, Correale, Jorge, additional, Coyle, Patricia K., additional, Cross, Anne H., additional, de Seze, Jérôme, additional, Leppert, David, additional, Montalban, Xavier, additional, Selmaj, Krzysztof, additional, Wiendl, Heinz, additional, Kakarieka, Algirdas, additional, Li, Bingbing, additional, Willi, Roman, additional, Häring, Dieter A., additional, Merschhemke, Martin, additional, and Kappos, Ludwig, additional

Published
2020
Full Text
View/download PDF

30. Clinically Meaningful Decline on SDMT Primarily Occurs Independently of Relapses and Is Slowed by Ocrelizumab in Patients with Multiple Sclerosis: Results from the Pooled OPERA Studies (1290)

Author

Benedict, Ralph, primary, de Seze, Jerome, additional, Hauser, Stephen L., additional, Hartung, Hans-Peter, additional, Kappos, Ludwig, additional, Overell, James, additional, Koendgen, Harold, additional, Wang, Qing, additional, Sauter, Annette, additional, Manfrini, Marianna, additional, and Cohan, Stanley, additional

Published
2020
Full Text
View/download PDF

32. Ofatumumab Reduces Disability Progression Independent of Relapse Activity in Patients with Relapsing Multiple Sclerosis (1845)

Author

Montalban, Xavier, primary, Cohen, Jeffrey A., additional, Comi, Giancarlo, additional, Coyle, Patricia K., additional, Kappos, Ludwig, additional, Li, Bingbing, additional, Sfikas, Nikolaos, additional, Willi, Roman, additional, Häring, Dieter A., additional, Merschhemke, Martin, additional, and Hauser, Stephen L., additional

Published
2020
Full Text
View/download PDF

33. Serum Ig Levels and Risk of Serious Infections by Baseline Ig Quartile in the Pivotal Phase III Trials and Open-Label Extensions of Ocrelizumab in Multiple Sclerosis (1173)

Author

Bar-Or, Amit, primary, Bermel, Robert, additional, Weber, Martin S., additional, Hughes, Richard, additional, Lin, Chien-Ju, additional, Wang, Jianmei, additional, Sauter, Annette, additional, Koendgen, Harold, additional, Craveiro, Licinio, additional, Hauser, Stephen L., additional, and Derfuss, Tobias, additional

Published
2020
Full Text
View/download PDF

35. Instrumental, Clinical, and Patient Reported Sensorimotor Correlates of Spinal Cord Grey and Total Cord Areas (P5.2-042)

Author

Alexander, Amber M., primary, Arjona, Jennifer, additional, Papinutto, Nico, additional, Stern, William, additional, Bischof, Antje, additional, Block, Valerie J., additional, Gelfand, Jeffrey, additional, Goodin, Douglas, additional, Jia, Xiaoming, additional, Romeo, Andrew, additional, Graves, Jennifer, additional, Cree, Bruce A.C., additional, Hauser, Stephen, additional, and Henry, Roland G., additional

Published
2019
Full Text
View/download PDF

36. Reduced Rate of Brain Atrophy in Patients With PPMS Receiving Ocrelizumab Earlier and Continuously Versus Those Initiating Ocrelizumab Later: Results of ORATORIO 5-Year Follow-Up (P3.2-042)

Author

Arnold, Douglas L., primary, Giovannoni, Gavin, additional, Hartung, Hans-Peter, additional, Hauser, Stephen L., additional, Kappos, Ludwig, additional, Montalban, Xavier, additional, Wolinsky, Jerry S., additional, Coutant, Karine, additional, Prajapati, Kalpesh, additional, Model, Fabian, additional, Mehta, Lahar, additional, and Traboulsee, Anthony, additional

Published
2019
Full Text
View/download PDF

37. Baseline Characteristics of Patients with Relapsing Multiple Sclerosis in ASCLEPIOS Phase 3 Trials of Ofatumumab Versus Teriflunomide (P3.2-096)

Author

Kappos, Ludwig, primary, Bar-Or, Amit, additional, Cohen, Jeffrey, additional, Comi, Giancarlo, additional, Correale, Jorge, additional, Coyle, Patricia K., additional, Cross, Anne H., additional, de Seze, Jerome, additional, Montalban, Xavier, additional, Selmaj, Krzysztof, additional, Wiendl, Heinz, additional, Leppert, David, additional, Kerloeguen, Cecile, additional, Willi, Roman, additional, Häring, Dieter A., additional, Tomic, Davorka, additional, Goodyear, Alexandra, additional, Merschhemke, Martin, additional, and Hauser, Stephen L., additional

Published
2019
Full Text
View/download PDF

38. Accelerated Cord Atrophy Precedes Conversion to Secondary Progressive Disease in Relapsing Multiple Sclerosis (S12.001)

Author

Bischof, Antje, primary, Papinutto, Nico, additional, Keshavan, Anisha, additional, Zhang, Xinheng, additional, Rajesh, Anand, additional, Sacco, Simone, additional, Kirkish, Gina, additional, Gundel, Tristan, additional, Stern, William, additional, Caverzasi, Eduardo, additional, Zhao, Chao, additional, Zhou, Yifan, additional, Lu, Ying, additional, Gomez, Refujia, additional, Ragan, Nicholas, additional, Santaniello, Adam, additional, Zhu, Alyssa, additional, Juwono, Jeremy, additional, Bevan, Carolyn, additional, Bove, Riley, additional, Crabtree-Hartman, Elizabeth, additional, Gelfand, Jeffrey, additional, Goodin, Douglas, additional, Graves, Jennifer, additional, Oksenberg, Jorge, additional, Waubant, Emmanuelle, additional, Wilson, Michael, additional, Zamvil, Scott, additional, Green, Ari, additional, Cree, Bruce, additional, Hauser, Stephen, additional, and Henry, Roland, additional

Published
2019
Full Text
View/download PDF

40. FLOODLIGHT: Smartphone-Based Self-Monitoring Is Accepted by Patients and Provides Meaningful, Continuous Digital Outcomes Augmenting Conventional In-Clinic Multiple Sclerosis Measures (P3.2-024)

Author

Montalban, Xavier, primary, Mulero, Patricia, additional, Midaglia, Luciana, additional, Graves, Jennifer, additional, Hauser, Stephen L., additional, Julian, Laura, additional, Baker, Mike, additional, Schadrack, Jan, additional, Gossens, Christian, additional, Scotland, Alf, additional, Lipsmeier, Florian, additional, Bernasconi, Corrado, additional, Belachew, Shibeshih, additional, and Lindemann, Michael, additional

Published
2019
Full Text
View/download PDF

43. Brain MRI Activity and Atrophy Measures in Patients Receiving Continuous Ocrelizumab or Switching From Interferon Beta-1a to Ocrelizumab Therapy in the Open-Label Extension Period of the Phase III Trials of Ocrelizumab in Patients With Relapsing Multiple Sclerosis (S6.002)

Author

Arnold, Douglas, primary, Kappos, Ludwig, additional, Hauser, Stephen, additional, Montalban, Xavier, additional, Traboulsee, Anthony, additional, Wolinsky, Jerry, additional, Levesque, Victoria, additional, Villoslada, Pablo, additional, Belachew, Shibeshih, additional, Model, Fabian, additional, Hubeaux, Stanislas, additional, and Bar-Or, Amit, additional

Published
2018
Full Text
View/download PDF

45. Annualized Relapse Rate and Confirmed Disability Progression in Patients Receiving Continuous Ocrelizumab or Switching From Interferon Beta-1a to Ocrelizumab Therapy in the Open-Label Extension Period of the Phase III Trials of Ocrelizumab in Patients With Relapsing Multiple Sclerosis (P1.366)

Author

Hauser, Stephen, primary, Brochet, Bruno, additional, Montalban, Xavier, additional, Naismith, Robert, additional, Wolinsky, Jerry, additional, Manfrini, Marianna, additional, Garas, Monika, additional, Villoslada, Pablo, additional, Model, Fabian, additional, Hubeaux, Stanislas, additional, and Kappos, Ludwig, additional

Published
2018
Full Text
View/download PDF

47. FLOODLIGHT: Remote Self-Monitoring Is Accepted by Patients and Provides Meaningful, Continuous Sensor-Based Outcomes Consistent With and Augmenting Conventional In-Clinic Measures (P4.382)

Author

Montalban, Xavier, primary, Mulero, Patricia, additional, Midaglia, Luciana, additional, Graves, Jennifer, additional, Hauser, Stephen, additional, Julian, Laura, additional, Baker, Mike, additional, Schadrack, Jan, additional, Gossens, Christian, additional, Scotland, Alf, additional, Lipsmeier, Florian, additional, Pointeau, Gregoire, additional, Bernasconi, Corrado, additional, Belachew, Shibeshih, additional, and Lindemann, Michael, additional

Published
2018
Full Text
View/download PDF

48. Ocrelizumab May Reduce Tissue Damage in Chronic Active Lesions as Measured by Change in T1 Hypo-Intensity of Slowly Evolving Lesions in Patients With Primary Progressive Multiple Sclerosis (P3.376)

Author

Elliott, Colm, primary, Wolinsky, Jerry, additional, Hauser, Stephen, additional, Kappos, Ludwig, additional, Barkhof, Frederik, additional, Model, Fabian, additional, Wei, Wei, additional, Bernasconi, Corrado, additional, Belachew, Shibeshih, additional, and Arnold, Douglas, additional

Published
2018
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results